New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2013
15:34 EDTVRSN, KLAC, PFG, RRC, BIDU, BMRN, MXIM, EMN, CERN, SBUX, EXPE, ALTR, RSG, CB, AMZNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Amazon (AMZN), consensus 9c; Starbucks (SBUX), consensus 48c; Baidu (BIDU), consensus $1.03; Chubb (CB), consensus $1.74; Cerner (CERN), consensus 63c; Range Resources (RRC), consensus 28c; Republic Services (RSG), consensus 40c; Eastman Chemical (EMN), consensus $1.57; Principal Financial Group (PFG), consensus 74c; Altera (ALTR), consensus 33c; Maxim Integrated Products (MXIM), consensus 42c; KLA-Tencor (KLAC), consensus 86c; Expedia (EXPE), consensus 23c; BioMarin Pharmaceutical (BMRN), consensus (29c); VeriSign (VRSN), consensus 54c.
News For AMZN;SBUX;BIDU;CB;CERN;RRC;RSG;EMN;PFG;ALTR;MXIM;KLAC;EXPE;BMRN;VRSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
August 24, 2015
18:02 EDTAMZNS&P 500 enters correction territory amid global growth concerns
Subscribe for More Information
14:52 EDTAMZNAmazon.com fades, levels to watch
Subscribe for More Information
13:54 EDTBMRNFly Watch: Sarepta upgraded ahead of FDA deadline on DMD drug
The 60-day FDA review period for Sarepta's (SRPT) rolling NDA submission for its Duchenne muscular dystrophy drug eteplirsen ends tomorrow, Tuesday, August 25. Piper Jaffray is among research firms taking a bullish stance on the stock ahead of tomorrow's deadline. BACKGROUND: Eteplirsen is an "exon skipping" treatment that attempts to bypass genetic mutations to allow improved functioning of the affected gene. On August 21, Sarepta announced that the FDA granted a rare pediatric disease designation for eteplirsen, in addition to its previous orphan designation and fast track status. Piper Jaffray's Edward Tenthoff noted today that the drug could see a February 2016 PDUFA date, potentially yielding "blockbuster sales" for the company. Importantly, BioMarin's (BMRN) drisapersen is slightly ahead of eteplirsen's approval process with a December 27 PDUFA date, posing a potential competitive risk for Sarepta. PDUFA dates are FDA deadlines for approving new drugs, normally coming within 6 or 10 months of an NDA acceptance depending on the drug's priority status. ANALYST TAKE: Tenthoff stated in note to investors this morning that he expects the Food and Drug Administration to accept the New Drug Application for Sarepta's eteplirsen at the end of its 60-day review period tomorrow. Additionally, Tenthoff sees a joint advisory committee for eteplirsen and the similar drisapersen from BioMarin on November 23-24. On May 19, Sarepta said it held pre-NDA meetings with the FDA, and Piper Jaffray said it believes the company has now met all of the agency's information requests. The analyst upgraded Sarepta to Overweight from Neutral and hiked his price target to $48 from $28 and now values eteplirsen at $1.3B, up from $919M previously. PRICE ACTION: Shares of Sarepta Therapeutics are up roughly 1% in intraday trading to $34.21. The stock jumped about 60% on May 20 after the company announced its mid-year NDA plans for eteplirsen. BioMarin shares, meanwhile, are down 2% to $123.59 this afternoon.
10:58 EDTAMZNStocks with call strike movement; AMZN TWTR
Subscribe for More Information
10:02 EDTAMZNAmazon.com levels to watch
Subscribe for More Information
07:42 EDTCERNCerner should be bought with valuation at multi-year low, says Piper Jaffray
Subscribe for More Information
07:02 EDTBMRNMedivation to acquire worldwide rights to Talazoparib from BioMarin
Medivation (MDVN) and BioMarin Pharmaceutical (BMRN) have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib, a highly-potent, orally-available poly ADP ribose polymerase inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis. Under the terms of the agreement, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory and sales-based milestones and mid-single digit royalties for talazoparib. At the closing of the transaction, Medivation will assume all financial obligations associated with the development and commercialization of talazoparib. The closing of the transaction is conditioned on the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is anticipated to close in 2015.
06:34 EDTAMZNIntel leads $100M funding round for Mirantis, WSJ reports
Subscribe for More Information
06:27 EDTAMZNRoku tops Google in streaming media device sales, Parks Associates says
Subscribe for More Information
06:08 EDTAMZNAmazon keeps pushing back Prime Fresh trial end date, Re/code reports
Subscribe for More Information
05:57 EDTBIDUStocks with implied volatility below IV index mean; BIDU GOOG
Stocks with implied volatility below IV index mean; Baidu (BIDU) 41, Google (GOOG) 31 according to iVolatility.
August 23, 2015
18:44 EDTAMZNACLU offers legal representation to Amazon employees
Subscribe for More Information
August 21, 2015
16:34 EDTAMZNMarket enters correction territory in worst week in four years
For the week, stocks plummeted amid concerns about a slowing Chinese economy and declining oil prices. MACRO NEWS: Monday, the Empire State manufacturing index crashed to -14.92 in August after rebounding to 3.86 in July from June's -1.98. The consensus estimate was 4.75, and the surprising drop puts the index at its lowest point since April 2009... Meanwhile, the NAHB homebuilder sentiment index rose to 61 in August from 60 in June, matching consensus estimates... Tuesday, July housing starts edged up 0.2% to 1.206M, beating consensus estimates for 1.180M in the best reading since October 2007. Building permits, however, fell 16.3% to 1.119M against expectations for 1.230M, while single family starts rose 12.8% and multifamily numbers fell 17.0%... Wednesday, the July consumer price index edged up 0.1% against expectations for 0.2% reading. The core reading, which excludes food and energy, also came in at 0.1% versus consensus estimates of 0.2%... Meanwhile, FOMC minutes showed no definitive indication of a September rate hike... Thursday, initial jobless claims rose to 277,000 from a revised 273,000, bringing the 4-week moving average to 271,500... The Philadelphia Fed index rose 2.6 points to 8.3 in August, beating expectations for a 7.5 reading... Friday, the PMI Manufacturing Index Flash for August came in at a level of 52.9, below the prior level of 53.8 and the consensus level of 54.2. COMPANY NEWS: Monday, Liberty Interactive (QVCA) announced an agreement to acquire zulily (ZU) for $18.75 per share in a deal valuing the online shopping site at $2.4B. The acquisition will be attributed to Liberty's QVC tracking stock, though the companies specified that QVC and zulily will operate as separate brands... Amazon (AMZN) founder and CEO Jeff Bezos downplayed a recent New York Times critique of the company's workplace practices, telling employees in an email that "the article doesn't describe the Amazon I know or the caring Amazonians I work with every day..." Tuesday, Wal-Mart (WMT) cut its full year earnings outlook, with company executives on a subsequent conference call expressing confidence in China but noting that Brazil and U.K. remain challenging markets for the company... Wednesday, Seagate Technology (STX) agreed to acquire Dot Hill Systems (HILL) for $9.75 per share, noting that it expects the deal to be non-GAAP EPS accretive in fiscal 2016... Thursday, Valeant (VRX) agreed to acquire Sprout Pharmaceuticals for roughly $1B in cash plus a profit-sharing agreement, adding that it expects to bring the company's recently-approved female sexual dysfunction drug Addyi to the U.S. by Q4... Friday, Steiner Leisure (STNR) entered into a definitive merger agreement where an affiliate of Catterton will acquire all of the outstanding shares of Steiner for $65 per share in cash. INDEXES: For the week, the Dow lost about 5.79% to close at 16,459.75, the Nasdaq declined about 6.71% to close at 4,706.04, and the S&P 500 fell about 5.73% to close at 1,970.89.
16:01 EDTAMZNOptions Update; August 21, 2015
Subscribe for More Information
13:50 EDTAMZNOn The Fly: Weekly technical notes, Gold, S&P 500, Germany, China, Energy
Subscribe for More Information
11:38 EDTAMZNAmazon.com heads back toward session lows
Subscribe for More Information
11:13 EDTAMZNStocks with call strike movement; AMZN TWTR
Subscribe for More Information
11:12 EDTAMZNQualcomm reportedly to enter consumer drone market
Subscribe for More Information
09:38 EDTBMRNUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
06:23 EDTBMRNUBS sees 'meaningful' upside to BioMarin on positive Hemophilia data
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use